Compare PNNT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | ARMP |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.6M | 199.7M |
| IPO Year | 2007 | 1996 |
| Metric | PNNT | ARMP |
|---|---|---|
| Price | $3.04 | $3.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $4.75 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 554.4K | 92.4K |
| Earning Date | 11-23-2026 | 11-11-2026 |
| Dividend Yield | ★ 15.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.32 | N/A |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $2.75 |
| 52 Week High | $6.58 | $14.98 |
| Indicator | PNNT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 42.33 |
| Support Level | $2.78 | $2.75 |
| Resistance Level | $3.89 | $5.63 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 59.35 | 41.55 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.